

Practitioner's Docket No. 00157-47577

COPY OF PAPERS
ORIGINALLY FILED

28/F
97D
5/23/02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 15 2002

In re application of: W. Marasco, et al.

Serial No.: 09/522,727

Group No.: 1644

Filed: March 10, 2000

Examiner Roark, J.

For: INTRABODY-MEDIATED CONTROL OF IMMUNE REACTIONS

TECH CENTER 1600/2900

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 5/3/02

Patricia W. Turner
(type or print name of person mailing paper)

Patricia W. Turner

Signature of person mailing paper

Assistant Commissioner for Patents
Washington, D.C. 20231

REVISED AMENDMENT UNDER C.F.R. § 1.825

In the response to the Notice to Comply with the Sequence Listing Requirements mailed December 11, 2001 and Notice of Non-Compliant Amendment mailed March 12, 2002, copies of which are attached hereto, Applicants enclose herewith a computer readable form and a paper copy of the "Sequence Listing" and a statement that the content of the paper and computer readable copies are the same.

Please delete the sequence listing and insert the attached sequence listing into the application.

IN THE SPECIFICATION:

Please substitute the following replacement paragraph for the paragraph bridging page 4, line 25 through page 5, line 6 of the above-identified application:

f1
The intrabody comprises whole antibodies, heavy chains, Fab' fragments, single-chain antibodies and diabodies. In one preferred method of the present invention, the intrabody comprises a single-chain antibody (sFv). If the target is a receptor, the antibody contains a leader sequence and an ER or Golgi appropriate retention signal, such as KDEL (SEQ ID NO: 17).